In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 143 for your search:
Cancer Type/Condition:  Lung cancer, small cell
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0908010555, NCT01757158

2.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CARBMI, NCT02103244

3.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Haema CBF SCLC UK/AS 01, NCT00168896

4.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: GLiang, NCT01498055

5.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2012-10-25, NCT01731548

6.

Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 12 to 80
Sponsor: Other
Protocol IDs: Bron/Lig/Tr-1, NCT01955824

7.

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: N0574, NCCTG-N0574, ACOSOG-N0574, CDR0000499633, NCI-2009-00653, NCT00377156

8.

Phase: Phase III
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: STAD-1, 2006-003995-36, NCT00526396

9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000588879, CALGB-30610, RTOG 0538, U10CA031946, NCT00632853

10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ELCWP 01994, NCT00658580

11.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT number 2007-006033-14, NCT00717938

12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 19 to 80
Sponsor: Other
Protocol IDs: CSCLC-0810, NCT00826644

13.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ZhejiangCH06, NCT01158170

14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-156, 2011-000850-48, NCT01450761

15.

Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCLC, NCT01487499

16.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: M12PHA, unknown, NCT01780675

17.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: immatureDC- HMO-CTIL, NCT00278018

18.

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0359-08-HMO-CTIL, NCT00722228

19.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 100138, 10-C-0138, NCT01143545

20.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BRD 08/9-O, NCT01221675

21.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2B3-101-CR-001, NCT01386580

22.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 14858, 2011-004155-39, NCT01573338

23.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 6889, CNPq 577582/2008-9, NCT01584115

24.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01985, U10CA021115, ECOG-E2511, CDR0000736704, E2511, NCT01642251

25.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 14631, I4J-MC-HHBE, 2012-003174-83, NCT01722292
1     
New Search